Cytek Biosciences, Inc. (NASDAQ: CTKB) reported Q2 EPS of ($0.03), $0.04 worse than the analyst estimate of $0.01. Revenue for the quarter came in at $49.69 million versus the consensus estimate of $45.71 million.

For earnings history and earnings-related data on Cytek Biosciences, Inc. (CTKB) click here.